The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

Oral semaglutide reduced major cardiovascular events by 14% in patients with type 2 diabetes over nearly 4 years. The trial involved 9650 patients with type 2 diabetes and cardiovascular or kidney ...

By binding to GLP-1 receptors in the brain, semaglutide initiates responses that lead to appetite suppression and weight loss. (credit: FitLiving graphics team) Semaglutide targets the areas in ...